Acorda discloses safety concerns for PD candidate tozadenant

Acorda Therapeutics Inc. (NASDAQ:ACOR) disclosed cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and in some cases associated with sepsis and death.

Among about 890 patients who received the selective adenosine A2A receptor (ADORA2A) antagonist across the company's Phase IIb and Phase III trials, Acorda reported 7 cases of sepsis in the tozadenant arms, 5 of which were fatal. Furthermore, 4 of the sepsis cases were associated with agranulocytosis, including 2 patients with no white blood cell counts at the time of the event...